Loading clinical trials...
Loading clinical trials...
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatme...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boehringer Ingelheim
Collaborators
NCT06513026 · Lactose Intolerance, Lactose Intolerant, and more
NCT07112339 · Diabetes Mellitus, Type 2
NCT06329375 · Diabetes Mellitus, Type 2, Food Insecurity, and more
NCT06945406 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
NCT06959901 · Obesity and Diabetes Mellitus, Type 2, Diabetes Prevention
1218.63.61005 Boehringer Ingelheim Investigational Site
Gosford, New South Wales
1218.63.61006 Boehringer Ingelheim Investigational Site
Herston, Queensland
1218.63.61003 Boehringer Ingelheim Investigational Site
Adelaide, South Australia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions